SELLAS Life Sciences Group, Inc. — Net Income by Fiscal Year
16 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/9765afb8-7d03-4788-ae6b-234d302406fb/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-26.9M | 2025-01-01 – 2025-12-31 | evidence 0001390478-26-000003 |
| FY 2024 | $-30.9M | 2024-01-01 – 2024-12-31 | evidence 0001390478-25-000003 |
| FY 2023 | $-37.3M | 2023-01-01 – 2023-12-31 | evidence 0001390478-24-000004 |
| FY 2022 | $-41.3M | 2022-01-01 – 2022-12-31 | evidence 0001390478-23-000005 |
| FY 2021 | $-20.7M | 2021-01-01 – 2021-12-31 | evidence 0001390478-22-000006 |
| FY 2020 | $-16.8M | 2020-01-01 – 2020-12-31 | evidence 0001390478-21-000007 |
| FY 2019 | $-19.3M | 2019-01-01 – 2019-12-31 | evidence 0001390478-20-000007 |
| FY 2018 | $-27.7M | 2018-01-01 – 2018-12-31 | evidence 0001390478-19-000017 |
| FY 2017 | $-23.8M | 2017-01-01 – 2017-12-31 | evidence 0001193125-18-117053 |
| FY 2016 | $-17.7M | 2016-01-01 – 2016-12-31 | evidence 0001193125-18-117053 |
| FY 2015 | $-63.9M | 2015-01-01 – 2015-12-31 | evidence 0001390478-16-000088 |
| FY 2014 | $-36.6M | 2014-01-01 – 2014-12-31 | evidence 0001390478-15-000012 |
| FY 2013 | $-76.7M | 2013-01-01 – 2013-12-31 | evidence 0001390478-14-000016 |
| FY 2012 | $-121.4M | 2003-01-01 – 2013-03-31 | evidence 0001193125-13-211191 |
| FY 2011 | $-102.0M | 2003-01-01 – 2012-03-31 | evidence 0001193125-12-231316 |
| FY 2010 | $-12.0M | 2010-01-01 – 2010-12-31 | evidence 0001193125-12-137599 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
SELLAS Life Sciences Group, Inc. — all facts · Revenue · Operating Income